R&D The conflict in the Middle East is exposing dangerous prepar... If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
R&D Reshoring the UK pharmaceutical supply chain for future resi... Questions of supply chain security and resiliency have been growing in recent years.
Market Access Advancing medicine requires more secure supply chains We stand at the threshold of a new era for pharmaceutical supply chains, driven by breakthroughs in personalised medicine, the rising prevalence of biologics, and the integration of digital
R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
